AI VIVO’s artificial intelligence may have found more drugs to fight COVID-19
AI VIVO (Cambridge, UK) says it is looking for pharma and biotech companies interested in working on therapeutic candidates that its artificial intelligence has identified as “top-ranked” for COVID-19.
The company says it has found that multiple groups around the world already are conducting clinical trials for 41 of the candidate drugs from its top-ranked list for COVID-19. AI VIVO officials say the overlap is significant because its ranking system is based on the company’s phenotypic drug discovery methodology and does not rely on any prior knowledge or known information related to the disease or compounds.
“This is a great validation of AI VIVO’s phenotypic approach to modeling diseases and the effects of drugs,” AI VIVO CEO Peyman Gifani said in a news release.